Building the UK’s First Female-Focused GLP-1 Program

Key Concepts

• GLP-1 (Glucagon-like peptide-1): A class of medications (agonists) primarily used for weight management and metabolic health.
• Gender-Specific Healthcare: The practice of tailoring medical treatments and research to the biological and physiological differences of women.
• Under-researched Conditions: Medical areas like PCOS (Polycystic Ovary Syndrome), endometriosis, and menopause that historically lack sufficient clinical data.
• Clinical Study Integration: The methodology of embedding patient care within a research framework to gather data while providing treatment.

The Genesis of She Med

The company was founded out of a personal frustration with the traditional healthcare system, where the speaker experienced being dismissed by medical professionals who attributed her health complications to gender-based stereotypes. Upon moving to the UK, the founders identified a significant gap in the market: while the majority of users of GLP-1 medications were women, there were no existing programs specifically designed to address female-centric health needs or biological responses to these drugs.

Addressing the Research Gap

A core argument presented is that women’s health—specifically regarding conditions like PCOS, endometriosis, and menopause—is chronically under-researched. The founders established She Med not just as a service provider, but as a research-driven entity. By launching their program as a clinical study, they aimed to bridge the data gap regarding how GLP-1s interact with female physiology.

Methodology: The Clinical Study Approach

The team adopted a research-first framework to ensure their program was evidence-based.

1. Identification of Need: Recognizing that GLP-1s represent a significant future in metabolic health.
2. Study Design: Integrating clinical research into the patient onboarding process to collect data on female-specific outcomes.
3. Scalability and Demand: The founders initially projected an enrollment of 1,000 participants. However, the market response was overwhelming; within 60 days of opening the study, they received over 16,000 applications.

Key Arguments and Perspectives

• Systemic Dismissal: The speaker highlights a pervasive issue in healthcare where women’s physical symptoms are frequently minimized or misattributed to psychological factors ("it might just all be in your head").
• Market Demand: The massive influx of applications (16,000 in two months) serves as empirical evidence that there is a massive, unmet demand for healthcare services that prioritize female-specific data and experiences.
• The Future of GLP-1s: The founders argue that because GLP-1 medications are becoming a cornerstone of modern metabolic treatment, it is imperative that their application is studied through a gender-specific lens rather than a "one-size-fits-all" approach.

Conclusion

The success of She Med’s initial study underscores a critical shift in the healthcare landscape: patients are actively seeking providers who acknowledge the biological nuances of women’s health. By combining the administration of GLP-1 medications with rigorous clinical research, the company is working to rectify the historical lack of data in women’s health, proving that there is both a moral and commercial imperative to prioritize female-focused medical programs.